AZTherapies Completes Enrollment for ALZT-OP1 Trial for Early Alzheimer’s

AZTherapies Completes Enrollment for ALZT-OP1 Trial for Early Alzheimer’s
AZTherapies has completed enrollment for its Phase 3 COGNITE trial, testing the safety and efficacy of its investigational ALZT-OP1 for the treatment of early Alzheimer’s disease (AD). A total of 620 participants were enrolled following the screening of 1,800 patients, the company said. “With the COGNITE trial now fully enrolled, we are one step closer to providing Alzheimer’s patients with new hope for a treatment and look forward to completing the trial in late 2020,” David R. Elmaleh, PhD, founder, CEO, and chairman of AZTherapies, said in a press release. In Alzheimer’s disease, the activation of brain immune cells such as astrocytes and microglia release excessive amounts of inflammation-causing molecules. These molecules, known as cytokines, can damage nerve cells. The accumulation of amyloid beta plaques — toxic clumps of amyloid beta protein in the brain, thought to underlie Alzheimer’s — also are known to trigger this neuroinflammatory process. ALZT-OP1 is a two-part therapy
Subscribe or to access all post and page content.